HeartMate Meets Its Match? HeartWare VAD Data Has Good Showing At AHA
This article was originally published in The Gray Sheet
Executive Summary
Thoratec's days monopolizing the ventricular assist device market with its HeartMate VAD technology appear to be numbered. That's the consensus out of last week's American Heart Association annual meeting, where upstart HeartWare reported impressive results for its next-generation VAD in late-stage heart failure patients waiting for a transplant.
You may also be interested in...
Thoratec Downplays Threats From Competing HeartWare Pump
Thoratec’s virtual monopoly in the LVAD market is about to end with the anticipated launch of HeartWare’s system this month or next, but executives are not displaying major concern.
FDA Panel Supports HeartWare VAD, Despite Trial Shortcomings
Benefits of HeartWare system, as well as the prospect of adding a competitive device to a market currently dominated by a single product, overshadow uncertainties from missing data, panelists vote.
HeartWare Gets FDA Panel Date For HVAD Heart Failure Implant
Advisory panel review April 25 could pave the way for PMA approval this year as a bridge to heart transplant.